Stealth BioTherapeutics to Report Full Year 2020 Financial Results on Tuesday, April 6, 2021
Stealth BioTherapeutics Corp (Nasdaq: MITO) will announce its full year 2020 financial results on April 6, 2021, before market opening. A conference call will follow at 8:30 am ET to discuss the results and provide a business update, accessible through dedicated phone lines and a live audio webcast. The company is focused on developing therapies for mitochondrial dysfunction, with key candidates including elamipretide for rare diseases and SBT-272 for neurodegenerative conditions. The firm aims to lead advancements in mitochondrial medicine.
- Company's lead product candidate, elamipretide, targets rare metabolic cardiomyopathies and ophthalmic diseases.
- Promising preclinical data for SBT-272 in ALS indicates potential for rare neurodegenerative diseases.
- None.
BOSTON, March 31, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report full year 2020 financial results on Tuesday, April 6, 2021, before the market opens.
Management will host a conference call at 8:30 am ET that day to discuss the financial results and provide a general business update. The call can be accessed by dialing (877)-407-0989 (domestic) or (201)-389-0921 (international) and referencing conference ID 13717131. A live audio webcast of the event can be accessed by visiting the Investors & News section of Stealth's Investor website, https://investor.stealthbt.com/. A replay of the webcast will be archived on Stealth's website for 30 days following the event.
About Stealth
We are a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are also involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne and Becker muscular dystrophies and Friedreich's ataxia, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical stage candidate, SBT-272, for rare neurodegenerative disease indications following promising preclinical data in amyotrophic lateral sclerosis, or ALS. Our pipeline compounds include SBT-259, which we are evaluating for rare peripheral neuropathies, and the SBT-550 series of compounds, which we plan to evaluate for rare neurodegenerative and ophthalmic indications. We have optimized our discovery platform to identify novel mitochondria-targeted compounds, which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria. We have assembled a highly experienced management team, board of directors and group of scientific advisors to help us achieve our mission of leading mitochondrial medicine.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-report-full-year-2020-financial-results-on-tuesday-april-6-2021-301260066.html
SOURCE Stealth BioTherapeutics Inc.
FAQ
When will Stealth BioTherapeutics report its 2020 financial results?
What time is the conference call for Stealth BioTherapeutics financial results?
What is the stock symbol for Stealth BioTherapeutics?
What is the focus of Stealth BioTherapeutics?
What are the main drug candidates of Stealth BioTherapeutics?
